Results 161 to 170 of about 8,373 (204)

Clinical significance of t(11;14) translocation in systemic AL amyloidosis in the era of daratumumab therapy. [PDF]

Clin Exp Med
Nishimura N, Kawano Y, Yasunaga JI.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immunoglobulin light chain amyloidosis

Expert Review of Hematology, 2013
Primary light chain amyloidosis is the most common form of systemic amyloidosis and is caused by misfolded light chains that cause proteotoxicity and rapid decline of vital organ function. Early diagnosis is essential in order to deliver effective therapy and prevent irreversible organ damage.
MERLINI, GIAMPAOLO, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA   +4 more
openaire   +3 more sources

Treatment of immunoglobulin light chain amyloidosis

Current Hematologic Malignancy Reports, 2009
No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients.
Morie A, Gertz, Steven R, Zeldenrust
openaire   +2 more sources

Immunoglobulin Light Chain Systemic Amyloidosis

2016
Immunoglobulin light chain amyloidosis (AL) is a rare, complex disease caused by misfolded free light chains produced by a usually small, indolent plasma cell clone. Effective treatments exist that can alter the natural history, provided that they are started before irreversible organ damage has occurred.
Angela, Dispenzieri, Giampaolo, Merlini
openaire   +2 more sources

Free Light Chains of Immunoglobulins in Amyloidosis

Acta Medica Scandinavica, 1979
ABSTRACT Monomeric (M) and dimeric (D) forms of free light chains in serum have been measured by a sensitive radioimmunoassay in eight patients with amyloidosis without monoclonal proteins. Significantly elevated concentrations of D lambda chains were demonstrated in two of four patients with localized amyloidosis.
J, Sølling, K, Sølling
openaire   +2 more sources

Systemic Immunoglobulin Light-Chain Amyloidosis

Clinical Lymphoma and Myeloma, 2006
Amyloidosis is a rare disease in which amyloid fibrils compromise organ function and lead to death. Systemic immunoglobulin light-chain amyloidosis, usually caused by free light chains (FLCs) made by clonal plasma cells, is the most frequent type. Hereditary and senile systemic amyloidosis are less frequent types.
openaire   +2 more sources

Stem cell transplantation for immunoglobulin light chain amyloidosis

Current Problems in Cancer, 2017
Systemic chemotherapy aimed at eradicating transformed plasma cells is the mainstay of treatment for immunoglobulin light chain amyloidosis (AL). Autologous stem cell transplantation (SCT) is a highly effective treatment for AL and can lead to long term survival in excess of 10 years in patients who achieve complete remission.
Taimur, Sher, Morie A, Gertz
openaire   +2 more sources

Glycosylation of immunoglobulin light chains associated with amyloidosis

Amyloid, 2000
AL amyloidosis is a fatal disease caused by deposition of immunoglobulin light chains in a fibrillarforin (AL) in various organs. By searching the Kabat database of immunoglobulin sequences using the KabatMan software, we have shown that there is a preponderance of the consensus glycosylation sequon (AsnXxxSer/Thr) in the framework regions of amyloid ...
L A, Omtvedt, D, Bailey, D V, Renouf, M J, Davies, N A, Paramonov, S, Haavik, G, Husby, K, Sletten, E F, Hounsell   +8 more
openaire   +2 more sources